BIOMAT Database Logo BIOMAT Database Logo

Detection of human T-cell lymphotropic virus type III-related antigens and anti-human T-cell lymphotropic virus type III antibodies by anticomplementary immunofluorescence. 1986

R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley

Techniques presently available for detection of human T-cell lymphotropic virus type III (HTLV-III) antigens and antibodies are laborious or relatively nonsensitive. We adapted anticomplementary immunofluorescence (ACIF) for these purposes. In HTLV-III-infected cells, specific ACIF was demonstrated by a diffuse speckling pattern that often resulted in a peripheral cellular rim of fluorescence. A 97% concordance was demonstrated between the ACIF assay and other sensitive tests for HTLV-III antibody detection (Western blot and membrane immunofluorescence and fixed-cell immunofluorescence tests). The ACIF assay was both more sensitive and more specific when compared with the enzyme-linked immunosorbent assay. For detection of HTLV-III antigens, the ACIF assay appeared to be as sensitive as the reverse transcriptase assay and more sensitive, with less background reactivity, than the conventional immunofluorescence assay. The ACIF assay often detected low levels of HTLV-III antigens within 3 days of infection in vitro, compared with 5 to 7 days with the indirect immunofluorescence assay, and generally paralleled the reverse transcriptase assay. The ACIF assay is a simple, sensitive, and specific assay for detection of HTLV-III-related antigens and antibodies. It should prove useful in the diagnosis of HTLV-III infection, as well as in studies of pathogenesis.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral

Related Publications

R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Antigens of human T-lymphotropic virus type III/lymphadenopathy-associated virus.
November 1985, Annals of internal medicine,
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Detection of antibodies to human T-lymphotropic virus type III in various non-human primates.
December 1985, The Japanese journal of experimental medicine,
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Detection and differentiation of antibodies to human T-cell lymphotropic virus types I and II by the immunofluorescence method.
October 1991, Journal of clinical microbiology,
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Human T-lymphotropic virus type III (HTLV-III).
January 1987, Hematologic pathology,
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Detection of human T-cell lymphotropic virus type I-related antibodies in patients with lymphocytic interstitial pneumonia.
December 1991, The American review of respiratory disease,
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM).
April 1986, Science (New York, N.Y.),
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Antibodies to human T lymphotropic virus type III demonstrated by a dot immunobinding assay.
March 1985, Scandinavian journal of immunology,
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Human T-cell lymphotropic virus type III (HTLV-III) core antigens: synthesis in Escherichia coli and immunoreactivity with human sera.
April 1986, DNA (Mary Ann Liebert, Inc.),
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
June 1985, Lancet (London, England),
R S Blumberg, and E G Sandstrom, and T J Paradis, and D N Neumeyer, and M G Sarngadharan, and K L Hartshorn, and R E Byington, and M S Hirsch, and R T Schooley
Detection of antibodies to human T-lymphotropic virus type I by using synthetic peptides.
May 1990, International journal of cancer,
Copied contents to your clipboard!